APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antidiabetic Biguanides

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Antidiabetic Biguanides Industry Growth and Trends Forecast to 2032

20 December 2025102 pages

Choose your research edition.

Industry ResearchAntidiabetic Biguanides Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Antidiabetic Biguanides Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Antidiabetic Biguanides Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antidiabetic Biguanides Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Antidiabetic Biguanides Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Antidiabetic Biguanides market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Antidiabetic Biguanides is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Antidiabetic Biguanides is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antidiabetic Biguanides is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antidiabetic Biguanides include Boehringer Ingelheim, Bristol-Myers Squibb, Novo Nordisk, Servier Laboratories, AstraZeneca, GlaxoSmithKline, Pfizer, Eli Lilly and Merck & Co, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Antidiabetic Biguanides market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Antidiabetic Biguanides market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antidiabetic Biguanides market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antidiabetic Biguanides.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Antidiabetic Biguanides market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Antidiabetic Biguanides Market by Company

Boehringer Ingelheim

Bristol-Myers Squibb

Novo Nordisk

Servier Laboratories

AstraZeneca

GlaxoSmithKline

Pfizer

Eli Lilly

Merck & Co

Sanofi

Takeda Pharmaceuticals

Antidiabetic Biguanides Segment by Type

Metformin IR

Metformin SR

Antidiabetic Biguanides Segment by Application

Hospitals

Clinics

Other

Antidiabetic Biguanides Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antidiabetic Biguanides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antidiabetic Biguanides and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antidiabetic Biguanides.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antidiabetic Biguanides manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Antidiabetic Biguanides in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Metformin IR Table 2. Major Company of Metformin SR Table 3. Global Antidiabetic Biguanides Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Antidiabetic Biguanides Sales by Type (2021-2026) & (K Units) Table 5. Global Antidiabetic Biguanides Sales Market Share in Volume by Type (2021-2026) Table 6. Global Antidiabetic Biguanides Sales by Type (2021-2026) & (US$ Million) Table 7. Global Antidiabetic Biguanides Sales Market Share in Value by Type (2021-2026) Table 8. Global Antidiabetic Biguanides Price by Type (2021-2026) & (US$/Unit) Table 9. Global Antidiabetic Biguanides Sales by Type (2027-2032) & (K Units) Table 10. Global Antidiabetic Biguanides Sales Market Share in Volume by Type (2027-2032) Table 11. Global Antidiabetic Biguanides Sales by Type (2027-2032) & (US$ Million) Table 12. Global Antidiabetic Biguanides Sales Market Share in Value by Type (2027-2032) Table 13. Global Antidiabetic Biguanides Price by Type (2027-2032) & (US$/Unit) Table 14. North America Antidiabetic Biguanides Sales by Type (2021-2026) & (K Units) Table 15. North America Antidiabetic Biguanides Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Antidiabetic Biguanides Sales by Type (2021-2026) & (K Units) Table 17. Europe Antidiabetic Biguanides Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Antidiabetic Biguanides Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Antidiabetic Biguanides Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Antidiabetic Biguanides Sales by Type (2021-2026) & (K Units) Table 21. Latin America Antidiabetic Biguanides Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Antidiabetic Biguanides Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Antidiabetic Biguanides Sales by Type (2021-2026) & (US$ Million) Table 24. Antidiabetic Biguanides Industry Trends Table 25. Antidiabetic Biguanides Industry Drivers Table 26. Antidiabetic Biguanides Industry Opportunities and Challenges Table 27. Antidiabetic Biguanides Industry Restraints Table 28. Global Antidiabetic Biguanides Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Antidiabetic Biguanides Revenue Market Share by Company (2021-2026) Table 30. Global Antidiabetic Biguanides Sales by Company (2021-2026) & (K Units) Table 31. Global Antidiabetic Biguanides Sales Share by Company (2021-2026) Table 32. Global Antidiabetic Biguanides Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Antidiabetic Biguanides Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Antidiabetic Biguanides Major Company Production Sites and Headquarters Table 35. Global Antidiabetic Biguanides Company, Product Type & Application Table 36. Global Antidiabetic Biguanides Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Antidiabetic Biguanides by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Antidiabetic Biguanides Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Antidiabetic Biguanides Sales by Region (2021-2026) & (K Units) Table 41. Global Antidiabetic Biguanides Sales Market Share in Volume by Region (2021-2026) Table 42. Global Antidiabetic Biguanides Sales by Region (2021-2026) & (US$ Million) Table 43. Global Antidiabetic Biguanides Sales Market Share in Value by Region (2021-2026) Table 44. Global Antidiabetic Biguanides Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Antidiabetic Biguanides Sales by Region (2027-2032) & (K Units) Table 46. Global Antidiabetic Biguanides Sales Market Share in Volume by Region (2027-2032) Table 47. Global Antidiabetic Biguanides Sales by Region (2027-2032) & (US$ Million) Table 48. Global Antidiabetic Biguanides Sales Market Share in Value by Region (2027-2032) Table 49. Global Antidiabetic Biguanides Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Antidiabetic Biguanides Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Antidiabetic Biguanides Sales by Application (2021-2026) & (K Units) Table 52. Global Antidiabetic Biguanides Sales Market Share in Volume by Application (2021-2026) Table 53. Global Antidiabetic Biguanides Sales by Application (2021-2026) & (US$ Million) Table 54. Global Antidiabetic Biguanides Sales Market Share in Value by Application (2021-2026) Table 55. Global Antidiabetic Biguanides Price by Application (2021-2026) & (US$/Unit) Table 56. Global Antidiabetic Biguanides Sales by Application (2027-2032) & (K Units) Table 57. Global Antidiabetic Biguanides Sales Market Share in Volume by Application (2027-2032) Table 58. Global Antidiabetic Biguanides Sales by Application (2027-2032) & (US$ Million) Table 59. Global Antidiabetic Biguanides Sales Market Share in Value by Application (2027-2032) Table 60. Global Antidiabetic Biguanides Price by Application (2027-2032) & (US$/Unit) Table 61. North America Antidiabetic Biguanides Sales by Application (2021-2026) & (K Units) Table 62. North America Antidiabetic Biguanides Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Antidiabetic Biguanides Sales by Application (2021-2026) & (K Units) Table 64. Europe Antidiabetic Biguanides Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Antidiabetic Biguanides Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Antidiabetic Biguanides Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Antidiabetic Biguanides Sales by Application (2021-2026) & (K Units) Table 68. Latin America Antidiabetic Biguanides Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Antidiabetic Biguanides Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Antidiabetic Biguanides Sales by Application (2021-2026) & (US$ Million) Table 71. Boehringer Ingelheim Company Information Table 72. Boehringer Ingelheim Business Overview Table 73. Boehringer Ingelheim Antidiabetic Biguanides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Boehringer Ingelheim Antidiabetic Biguanides Product Portfolio Table 75. Boehringer Ingelheim Recent Development Table 76. Bristol-Myers Squibb Company Information Table 77. Bristol-Myers Squibb Business Overview Table 78. Bristol-Myers Squibb Antidiabetic Biguanides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Bristol-Myers Squibb Antidiabetic Biguanides Product Portfolio Table 80. Bristol-Myers Squibb Recent Development Table 81. Novo Nordisk Company Information Table 82. Novo Nordisk Business Overview Table 83. Novo Nordisk Antidiabetic Biguanides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Novo Nordisk Antidiabetic Biguanides Product Portfolio Table 85. Novo Nordisk Recent Development Table 86. Servier Laboratories Company Information Table 87. Servier Laboratories Business Overview Table 88. Servier Laboratories Antidiabetic Biguanides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Servier Laboratories Antidiabetic Biguanides Product Portfolio Table 90. Servier Laboratories Recent Development Table 91. AstraZeneca Company Information Table 92. AstraZeneca Business Overview Table 93. AstraZeneca Antidiabetic Biguanides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. AstraZeneca Antidiabetic Biguanides Product Portfolio Table 95. AstraZeneca Recent Development Table 96. GlaxoSmithKline Company Information Table 97. GlaxoSmithKline Business Overview Table 98. GlaxoSmithKline Antidiabetic Biguanides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. GlaxoSmithKline Antidiabetic Biguanides Product Portfolio Table 100. GlaxoSmithKline Recent Development Table 101. Pfizer Company Information Table 102. Pfizer Business Overview Table 103. Pfizer Antidiabetic Biguanides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Pfizer Antidiabetic Biguanides Product Portfolio Table 105. Pfizer Recent Development Table 106. Eli Lilly Company Information Table 107. Eli Lilly Business Overview Table 108. Eli Lilly Antidiabetic Biguanides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Eli Lilly Antidiabetic Biguanides Product Portfolio Table 110. Eli Lilly Recent Development Table 111. Merck & Co Company Information Table 112. Merck & Co Business Overview Table 113. Merck & Co Antidiabetic Biguanides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Merck & Co Antidiabetic Biguanides Product Portfolio Table 115. Merck & Co Recent Development Table 116. Sanofi Company Information Table 117. Sanofi Business Overview Table 118. Sanofi Antidiabetic Biguanides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Sanofi Antidiabetic Biguanides Product Portfolio Table 120. Sanofi Recent Development Table 121. Takeda Pharmaceuticals Company Information Table 122. Takeda Pharmaceuticals Business Overview Table 123. Takeda Pharmaceuticals Antidiabetic Biguanides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Takeda Pharmaceuticals Antidiabetic Biguanides Product Portfolio Table 125. Takeda Pharmaceuticals Recent Development Table 126. North America Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 127. North America Antidiabetic Biguanides Sales by Country (2021-2026) & (K Units) Table 128. North America Antidiabetic Biguanides Sales Market Share by Country (2021-2026) Table 129. North America Antidiabetic Biguanides Sales Forecast by Country (2027-2032) & (K Units) Table 130. North America Antidiabetic Biguanides Sales Market Share Forecast by Country (2027-2032) Table 131. North America Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. North America Antidiabetic Biguanides Market Size by Country (2021-2026) & (US$ Million) Table 133. North America Antidiabetic Biguanides Market Share by Country (2021-2026) Table 134. North America Antidiabetic Biguanides Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. North America Antidiabetic Biguanides Market Share Forecast by Country (2027-2032) Table 136. Europe Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 137. Europe Antidiabetic Biguanides Sales by Country (2021-2026) & (K Units) Table 138. Europe Antidiabetic Biguanides Sales Market Share by Country (2021-2026) Table 139. Europe Antidiabetic Biguanides Sales Forecast by Country (2027-2032) & (K Units) Table 140. Europe Antidiabetic Biguanides Sales Market Share Forecast by Country (2027-2032) Table 141. Europe Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Europe Antidiabetic Biguanides Market Size by Country (2021-2026) & (US$ Million) Table 143. Europe Antidiabetic Biguanides Market Share by Country (2021-2026) Table 144. Europe Antidiabetic Biguanides Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Europe Antidiabetic Biguanides Market Share Forecast by Country (2027-2032) Table 146. Asia-Pacific Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 147. Asia-Pacific Antidiabetic Biguanides Sales by Country (2021-2026) & (K Units) Table 148. Asia-Pacific Antidiabetic Biguanides Sales Market Share by Country (2021-2026) Table 149. Asia-Pacific Antidiabetic Biguanides Sales Forecast by Country (2027-2032) & (K Units) Table 150. Asia-Pacific Antidiabetic Biguanides Sales Market Share Forecast by Country (2027-2032) Table 151. Asia-Pacific Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Asia-Pacific Antidiabetic Biguanides Market Size by Country (2021-2026) & (US$ Million) Table 153. Asia-Pacific Antidiabetic Biguanides Market Share by Country (2021-2026) Table 154. Asia-Pacific Antidiabetic Biguanides Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Asia-Pacific Antidiabetic Biguanides Market Share Forecast by Country (2027-2032) Table 156. Latin America Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 157. Latin America Antidiabetic Biguanides Sales by Country (2021-2026) & (K Units) Table 158. Latin America Antidiabetic Biguanides Sales Market Share by Country (2021-2026) Table 159. Latin America Antidiabetic Biguanides Sales Forecast by Country (2027-2032) & (K Units) Table 160. Latin America Antidiabetic Biguanides Sales Market Share Forecast by Country (2027-2032) Table 161. Latin America Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Latin America Antidiabetic Biguanides Market Size by Country (2021-2026) & (US$ Million) Table 163. Latin America Antidiabetic Biguanides Market Share by Country (2021-2026) Table 164. Latin America Antidiabetic Biguanides Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Latin America Antidiabetic Biguanides Market Share Forecast by Country (2027-2032) Table 166. Middle East and Africa Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 167. Middle East and Africa Antidiabetic Biguanides Sales by Country (2021-2026) & (K Units) Table 168. Middle East and Africa Antidiabetic Biguanides Sales Market Share by Country (2021-2026) Table 169. Middle East and Africa Antidiabetic Biguanides Sales Forecast by Country (2027-2032) & (K Units) Table 170. Middle East and Africa Antidiabetic Biguanides Sales Market Share Forecast by Country (2027-2032) Table 171. Middle East and Africa Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 172. Middle East and Africa Antidiabetic Biguanides Market Size by Country (2021-2026) & (US$ Million) Table 173. Middle East and Africa Antidiabetic Biguanides Market Share by Country (2021-2026) Table 174. Middle East and Africa Antidiabetic Biguanides Market Size Forecast by Country (2027-2032) & (US$ Million) Table 175. Middle East and Africa Antidiabetic Biguanides Market Share Forecast by Country (2027-2032) Table 176. Key Raw Materials Table 177. Raw Materials Key Suppliers Table 178. Antidiabetic Biguanides Distributors List Table 179. Antidiabetic Biguanides Customers List Table 180. Research Programs/Design for This Report Table 181. Authors List of This Report Table 182. Secondary Sources Table 183. Primary Sources List of Figures Figure 1. Antidiabetic Biguanides Image Figure 2. Global Antidiabetic Biguanides Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antidiabetic Biguanides Market Size (2021-2032) & (US$ Million) Figure 4. Global Antidiabetic Biguanides Sales (2021-2032) & (K Units) Figure 5. Metformin IR Image Figure 6. Global Metformin IR Sales YoY Growth (2021-2032) & (K Units) Figure 7. Metformin SR Image Figure 8. Global Metformin SR Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Antidiabetic Biguanides Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Antidiabetic Biguanides Market Share by Type 2025 VS 2032 Figure 11. North America Antidiabetic Biguanides Sales Market Share in Volume by Type in 2025 Figure 12. North America Antidiabetic Biguanides Sales Market Share in Value by Type in 2025 Figure 13. Europe Antidiabetic Biguanides Sales Market Share in Volume by Type in 2025 Figure 14. Europe Antidiabetic Biguanides Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Antidiabetic Biguanides Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Antidiabetic Biguanides Sales Market Share in Value by Type in 2025 Figure 17. Latin America Antidiabetic Biguanides Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Antidiabetic Biguanides Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Antidiabetic Biguanides Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Antidiabetic Biguanides Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Antidiabetic Biguanides Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospitals Image Figure 24. Global Hospitals Sales YoY Growth (2021-2032) & (K Units) Figure 25. Clinics Image Figure 26. Global Clinics Sales YoY Growth (2021-2032) & (K Units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Antidiabetic Biguanides Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Antidiabetic Biguanides Market Share by Application 2025 VS 2032 Figure 31. North America Antidiabetic Biguanides Sales Market Share in Volume by Application in 2025 Figure 32. North America Antidiabetic Biguanides Sales Market Share in Value by Application in 2025 Figure 33. Europe Antidiabetic Biguanides Sales Market Share in Volume by Application in 2025 Figure 34. Europe Antidiabetic Biguanides Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Antidiabetic Biguanides Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Antidiabetic Biguanides Sales Market Share in Value by Application in 2025 Figure 37. Latin America Antidiabetic Biguanides Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Antidiabetic Biguanides Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Antidiabetic Biguanides Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Antidiabetic Biguanides Sales Market Share in Value by Application in 2025 Figure 41. North America Antidiabetic Biguanides Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Antidiabetic Biguanides Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Antidiabetic Biguanides Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Antidiabetic Biguanides Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Antidiabetic Biguanides Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Antidiabetic Biguanides Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Antidiabetic Biguanides Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Antidiabetic Biguanides Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Antidiabetic Biguanides Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Antidiabetic Biguanides Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Antidiabetic Biguanides Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Antidiabetic Biguanides Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Antidiabetic Biguanides Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Antidiabetic Biguanides Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Antidiabetic Biguanides Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Antidiabetic Biguanides Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Antidiabetic Biguanides Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Antidiabetic Biguanides Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Antidiabetic Biguanides Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Antidiabetic Biguanides Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Antidiabetic Biguanides Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Antidiabetic Biguanides Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Metformin IR
  • Metformin SR
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Novo Nordisk
  • Servier Laboratories
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly
  • Merck & Co
  • Sanofi
  • Takeda Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antidiabetic Biguanides Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Antidiabetic Biguanides Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Antidiabetic Biguanides Market by Type
  6. 1.3.1 Metformin IR
  7. 1.3.2 Metformin SR
  8. 1.4 Global Antidiabetic Biguanides Market Size by Type
  9. 1.4.1 Global Antidiabetic Biguanides Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Antidiabetic Biguanides Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Antidiabetic Biguanides Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Antidiabetic Biguanides Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Antidiabetic Biguanides Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Antidiabetic Biguanides Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Antidiabetic Biguanides Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Antidiabetic Biguanides Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Antidiabetic Biguanides Industry Trends
  2. 2.2 Antidiabetic Biguanides Industry Drivers
  3. 2.3 Antidiabetic Biguanides Industry Opportunities and Challenges
  4. 2.4 Antidiabetic Biguanides Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Antidiabetic Biguanides Revenue (2021-2026)
  2. 3.2 Global Top Players by Antidiabetic Biguanides Sales (2021-2026)
  3. 3.3 Global Top Players by Antidiabetic Biguanides Price (2021-2026)
  4. 3.4 Global Antidiabetic Biguanides Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antidiabetic Biguanides Major Company Production Sites & Headquarters
  6. 3.6 Global Antidiabetic Biguanides Company, Product Type & Application
  7. 3.7 Global Antidiabetic Biguanides Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antidiabetic Biguanides Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antidiabetic Biguanides Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antidiabetic Biguanides Tier 1, Tier 2, and Tier 3
4 Antidiabetic Biguanides Regional Status and Outlook
  1. 4.1 Global Antidiabetic Biguanides Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Antidiabetic Biguanides Historic Market Size by Region
  3. 4.2.1 Global Antidiabetic Biguanides Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Antidiabetic Biguanides Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Antidiabetic Biguanides Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Antidiabetic Biguanides Forecasted Market Size by Region
  7. 4.3.1 Global Antidiabetic Biguanides Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Antidiabetic Biguanides Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Antidiabetic Biguanides Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Antidiabetic Biguanides by Application
  1. 5.1 Antidiabetic Biguanides Market by Application
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Other
  5. 5.2 Global Antidiabetic Biguanides Market Size by Application
  6. 5.2.1 Global Antidiabetic Biguanides Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Antidiabetic Biguanides Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Antidiabetic Biguanides Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Antidiabetic Biguanides Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Antidiabetic Biguanides Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Antidiabetic Biguanides Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Antidiabetic Biguanides Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Antidiabetic Biguanides Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Boehringer Ingelheim
  2. 6.1.1 Boehringer Ingelheim Company Information
  3. 6.1.2 Boehringer Ingelheim Business Overview
  4. 6.1.3 Boehringer Ingelheim Antidiabetic Biguanides Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Boehringer Ingelheim Antidiabetic Biguanides Product Portfolio
  6. 6.1.5 Boehringer Ingelheim Recent Developments
  7. 6.2 Bristol-Myers Squibb
  8. 6.2.1 Bristol-Myers Squibb Company Information
  9. 6.2.2 Bristol-Myers Squibb Business Overview
  10. 6.2.3 Bristol-Myers Squibb Antidiabetic Biguanides Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Bristol-Myers Squibb Antidiabetic Biguanides Product Portfolio
  12. 6.2.5 Bristol-Myers Squibb Recent Developments
  13. 6.3 Novo Nordisk
  14. 6.3.1 Novo Nordisk Company Information
  15. 6.3.2 Novo Nordisk Business Overview
  16. 6.3.3 Novo Nordisk Antidiabetic Biguanides Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Novo Nordisk Antidiabetic Biguanides Product Portfolio
  18. 6.3.5 Novo Nordisk Recent Developments
  19. 6.4 Servier Laboratories
  20. 6.4.1 Servier Laboratories Company Information
  21. 6.4.2 Servier Laboratories Business Overview
  22. 6.4.3 Servier Laboratories Antidiabetic Biguanides Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Servier Laboratories Antidiabetic Biguanides Product Portfolio
  24. 6.4.5 Servier Laboratories Recent Developments
  25. 6.5 AstraZeneca
  26. 6.5.1 AstraZeneca Company Information
  27. 6.5.2 AstraZeneca Business Overview
  28. 6.5.3 AstraZeneca Antidiabetic Biguanides Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 AstraZeneca Antidiabetic Biguanides Product Portfolio
  30. 6.5.5 AstraZeneca Recent Developments
  31. 6.6 GlaxoSmithKline
  32. 6.6.1 GlaxoSmithKline Company Information
  33. 6.6.2 GlaxoSmithKline Business Overview
  34. 6.6.3 GlaxoSmithKline Antidiabetic Biguanides Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 GlaxoSmithKline Antidiabetic Biguanides Product Portfolio
  36. 6.6.5 GlaxoSmithKline Recent Developments
  37. 6.7 Pfizer
  38. 6.7.1 Pfizer Company Information
  39. 6.7.2 Pfizer Business Overview
  40. 6.7.3 Pfizer Antidiabetic Biguanides Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Pfizer Antidiabetic Biguanides Product Portfolio
  42. 6.7.5 Pfizer Recent Developments
  43. 6.8 Eli Lilly
  44. 6.8.1 Eli Lilly Company Information
  45. 6.8.2 Eli Lilly Business Overview
  46. 6.8.3 Eli Lilly Antidiabetic Biguanides Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Eli Lilly Antidiabetic Biguanides Product Portfolio
  48. 6.8.5 Eli Lilly Recent Developments
  49. 6.9 Merck & Co
  50. 6.9.1 Merck & Co Company Information
  51. 6.9.2 Merck & Co Business Overview
  52. 6.9.3 Merck & Co Antidiabetic Biguanides Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Merck & Co Antidiabetic Biguanides Product Portfolio
  54. 6.9.5 Merck & Co Recent Developments
  55. 6.10 Sanofi
  56. 6.10.1 Sanofi Company Information
  57. 6.10.2 Sanofi Business Overview
  58. 6.10.3 Sanofi Antidiabetic Biguanides Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Sanofi Antidiabetic Biguanides Product Portfolio
  60. 6.10.5 Sanofi Recent Developments
  61. 6.11 Takeda Pharmaceuticals
  62. 6.11.1 Takeda Pharmaceuticals Company Information
  63. 6.11.2 Takeda Pharmaceuticals Business Overview
  64. 6.11.3 Takeda Pharmaceuticals Antidiabetic Biguanides Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Takeda Pharmaceuticals Antidiabetic Biguanides Product Portfolio
  66. 6.11.5 Takeda Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America Antidiabetic Biguanides Sales by Country
  2. 7.1.1 North America Antidiabetic Biguanides Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Antidiabetic Biguanides Sales by Country (2021-2026)
  4. 7.1.3 North America Antidiabetic Biguanides Sales Forecast by Country (2027-2032)
  5. 7.2 North America Antidiabetic Biguanides Market Size by Country
  6. 7.2.1 North America Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Antidiabetic Biguanides Market Size by Country (2021-2026)
  8. 7.2.3 North America Antidiabetic Biguanides Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Antidiabetic Biguanides Sales by Country
  2. 8.1.1 Europe Antidiabetic Biguanides Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Antidiabetic Biguanides Sales by Country (2021-2026)
  4. 8.1.3 Europe Antidiabetic Biguanides Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Antidiabetic Biguanides Market Size by Country
  6. 8.2.1 Europe Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Antidiabetic Biguanides Market Size by Country (2021-2026)
  8. 8.2.3 Europe Antidiabetic Biguanides Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Antidiabetic Biguanides Sales by Country
  2. 9.1.1 Asia-Pacific Antidiabetic Biguanides Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Antidiabetic Biguanides Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Antidiabetic Biguanides Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Antidiabetic Biguanides Market Size by Country
  6. 9.2.1 Asia-Pacific Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Antidiabetic Biguanides Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Antidiabetic Biguanides Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Antidiabetic Biguanides Sales by Country
  2. 10.1.1 South America Antidiabetic Biguanides Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Antidiabetic Biguanides Sales by Country (2021-2026)
  4. 10.1.3 South America Antidiabetic Biguanides Sales Forecast by Country (2027-2032)
  5. 10.2 South America Antidiabetic Biguanides Market Size by Country
  6. 10.2.1 South America Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Antidiabetic Biguanides Market Size by Country (2021-2026)
  8. 10.2.3 South America Antidiabetic Biguanides Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Antidiabetic Biguanides Sales by Country
  2. 11.1.1 Middle East and Africa Antidiabetic Biguanides Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Antidiabetic Biguanides Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Antidiabetic Biguanides Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Antidiabetic Biguanides Market Size by Country
  6. 11.2.1 Middle East and Africa Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Antidiabetic Biguanides Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Antidiabetic Biguanides Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Antidiabetic Biguanides Value Chain Analysis
  2. 12.1.1 Antidiabetic Biguanides Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Antidiabetic Biguanides Production Mode & Process
  7. 12.2 Antidiabetic Biguanides Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Antidiabetic Biguanides Distributors
  10. 12.2.3 Antidiabetic Biguanides Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst